A Study to Evaluate the Efficacy and Safety of AD-218

Recruiting now · Phase 3

Conditions studied: Mixed Dyslipidemia

In brief

The purpose of this study is to evaluate the efficacy and safety of AD-218

Key facts

Study ID

NCT05400317

Run by

Addpharma Inc.

People needed

520

Starts

2022-07-27

Expected to finish

2026-06-30

Last updated by the study team

2025-02-05

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• A man or woman over 19 years old.
• Sign on ICF prior to study participation

You may not qualify if…

• History of Fibromyalgia, Myopathy etc (CK ≥ 2 X ULN)
• Other exclusions applied

Where it is running

• Yeongnam University Hospital — Daegu, Nam-gu, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.